Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|October 24, 2007
Total upper and lower eyelid replacement following thermal burn using an ALT flap--a case reportC Rubino, F Farace, A Puddu, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1992
Studies on NK cell purification by negative selection in human peripheral bloodF Farace, A M Le Ridant, B Escudier, et al.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|March 21, 2009
[Potential role of antiangiogenic treatment in neuroblastoma]M Taylor, B Geoerger, J Lagodny, et al.
International Journal of Cancer|June 15, 1994
Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma: immunological monitoringF Farace, M Pallardy, E Angevin, et al.
European Journal of Immunology|December 1, 1986
A 93-kDa glycoprotein expressed on human cultured monocytes and dendritic reticulum cells defined by an anti-K562 monoclonal antibodyF Farace, N Kieffer, B Caillou, et al.
Acta Chirurgiae Plasticae|February 18, 2005
Treatment of non-melanoma skin cancer in North Sardinia: is there a need for biopsy?C Rubino, D Soggiu, F Farace, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 28, 1998
T-cell clonal expansion in patients with B-cell lymphoproliferative disordersN Alatrakchi, F Farace, E Frau, et al.
Bone Marrow Transplantation|October 1, 1995
Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastomaD Valteau-Couanet, H Rubie, V Meresse, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2B Escudier, F Farace, E Angevin, et al.
British Journal of Cancer|October 6, 2011
Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancerA Lecharpentier, P Vielh, P Perez-Moreno, et al.
Pageof 6